Table 3.
Variables related to the development of moderate to severe cGVHD
| Risk factors | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Patient age | ||||||
| < 50 years | 1 | |||||
| ≥ 50 years | 1.18 | 0.55–2.50 | 0.662 | |||
| Donor age | ||||||
| < 50 years | 1 | |||||
| ≥ 50 years | 0.874 | 0.45–1.67 | 0.686 | |||
| Blood transfusions | ||||||
| < 76 | 1 | |||||
| ≥ 76 | 0.38 | 0.09–1.61 | 0.192 | |||
| HLA antibodies in the recipienta | ||||||
| HLA antibodies negative | 1 | |||||
| HLA antibodies positive | 2.49 | 1.22–5.08 | 0.012 | 2.34 | 1.11–4.95 | 0.026 |
| Donor/recipient CMV status | ||||||
| Matched | 1 | |||||
| Mismatched | 1.04 | 0.37–2.94 | 0.935 | |||
| Donor/recipient gender | ||||||
| Matched | 1 | |||||
| Female to male | 1.80 | 0.93–3.48 | 0.081 | |||
| Type of donor | ||||||
| SIB | 1 | |||||
| MUD | 1.36 | 0.72–2.59 | 0.342 | |||
| DPB1 | ||||||
| Match | 1 | |||||
| Permissive | 1.13 | 0.51–2.53 | 0.768 | |||
| Non-permissive | 1.40 | 0.60–3.28 | 0.441 | |||
| Permissive/non-permissive | 1.24 | 0.65–2.38 | 0.519 | |||
| Infused cells in the recipient: | ||||||
| CD3 + 106/kg < 325 | 1 | |||||
| CD3 + 106/kg ≥ 325 | 3.06 | 1.56–6.00 | 0.001 | 2.18 | 1.04–4.59 | 0.040 |
| CD19 + 106/kg < 82 | 1 | |||||
| CD19 + 106/kg≥ 82 | 3.77 | 1.93–7.37 | 0.000 | 2.79 | 1.35–5.74 | 0.005 |
| CD34 + 106/kg < 8.6 | 1 | |||||
| CD34 + 106/kg ≥ 8.6 | 1.47 | 0.73–2.97 | 0.281 | |||
| GVHD | ||||||
| No acute GVHD | 1 | |||||
| Acute GVHD | 0.84 | 0.42–1.66 | 0.612 | |||
Total of infused cells boundaries were determined based on Q75 for all cells
HLA human leukocyte antigen, CMV cytomegalovirus, GVHD graft-versus-host disease
aHLA antibodies found prior to transplantation in the serum
Bold values indicate that statistical significance P < 0.05)